Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Investor Day (2021)
68 slides from Fisher & Paykel Healthcare's investor day presentation, 2021
Slide 1: Welcome to the Fisher & Paykel Healthcare Virtual Investor Series
Welcome to the Welcome to the Fisher & Paykel Fisher & Paykel Healthcare Healthcare Virtual Investor Series Virtual Investor Series Andrew Somervell – Vice President Products and Technology Andrew Somervell – Vice President Products and Technology
Slide 2: Our purpose
Our purpose Improving care & outcomes through inspired and world-leading healthcare solutions
Slide 3: Our strategy
Our strategy We aim to grow our business in a way that is sustainable over the long term by creating better products, extending our global reach and changing clinical practice.
Slide 4: Our aspiration
Our aspiration We’ve established an enviable track record for delivering SUSTAINABLE REVENUE GROWTH.
Slide 5: Hospital respiratory support
Hospital respiratory support Where will sustainable growth come from in the SHORT-TERM?
Slide 6: Home respiratory support
Home respiratory support Where will sustainable growth come from in the MEDIUM-TERM?
Slide 7: Surgical technologies
Surgical technologies Where will sustainable growth come from in the LONGER-TERM?
Slide 8: Our aspiration
Our aspiration OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years. *CONSTANT CURRENCY
Slide 9: Our strategy
Our strategy OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare solutions
Slide 10: A patient centred approach
A patient centred approach Patient Care is Complex Doing the right thing for our patients All parties want the best outcome for patients Complexity provides opportunity Leads to long term thinking Deep understanding of patients and their care New Insight / Original Thought Valued, Protected Differen
Slide 11: Virtual investor series itinerary
Virtual investor series itinerary Day 1 – Changing clinical practice / Better products • Optiflow: Hospital Respiratory Support – Sam Frame Day 2 – Changing clinical practice / Better products • Optiflow: Home Respiratory Support – Rob Kirton • Surgical – Winston Fong (VP Surgical Technologies) Day
Slide 12: Optiflow Nasal High Flow therapy
Optiflow™ Nasal High Flow therapy Sam Frame Marketing Manager – Optiflow and Airvo
Slide 13: Hospital Respiratory Support
Hospital Respiratory Support OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare solutions
Slide 14: Changing Clinical Practice
Changing Clinical Practice Changing clinical practice is difficult OUR PURPOSE Improving care & Global practice change outcomes through inspired and world- leading healthcare solutions Local practice change
Slide 15: Global Practice Change
Global Practice Change Guideline Systematic review with meta-analysis Systematic review Clinical outcome controlled trial Physiological/Pilot controlled trial Observational study/Cohort study Case report/Case series Editorial/Commentary/Opinion/Narrative Benchtop/descriptive study
Slide 16: Global Practice Change
Global Practice Change Publications featuring NHF for respiratory support in Adults Guideline Guideline Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observational Observational study/Cohor
Slide 17: Global Practice Change
Global Practice Change Publications featuring NHF for respiratory support in Adults Guideline Guideline Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observational Observational study/Cohor
Slide 18: Global Practice Change
Global Practice Change Publications featuring NHF for respiratory support in Adults Guideline Guideline Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observational Observational study/Cohor
Slide 19: Local Practice Change
Local Practice Change Requires us to change practice hospital by hospital
Slide 20: Changing Clinical Practice
Changing Clinical Practice Changing clinical practice is difficult Global practice GLOBAL LOCAL change helps local PRACTICE PRACTICE CHANGE CHANGE Local practice change helps global
Slide 21: Better products
Better products Optiflow systems Applying our expertise OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare Broad application solutions Adoption
Slide 22: Airvo Optiflow System
Airvo Optiflow System F&P Airvo 2 F&P Optiflow 3 interface F&P AirSpiral™ tube and chamber kit Fisher &Paykel HEALTHCARE
Slide 23: Humidification
Humidification Fisher &Paykel HEALTHCARE
Slide 24: Broad application
Broad application Rochwerg B, et al. Intensive Care Medicine. 2020. The role for high flow nasal cannula as a respiratory support strategy in adults Acute hypoxemic Post-operative Peri-intubation Post-extubation respiratory failure NHF is preferred to COT in high No recommendation is respiratory fai
Slide 25: Adoption
Adoption Publications featuring NHF for respiratory support in Adults Guideline Guideline Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observational Observational study/Cohort study Case r
Slide 26: Adoption
Adoption Publications featuring NHF for respiratory support in Adults Guideline Guideline Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observational Observational study/Cohort study Case r
Slide 27: Broad application
Broad application Fisher &Paykel HEALTHCARE
Slide 28: Broad application
Broad application Rochwerg B, et al. Intensive Care Medicine. 2020. The role for high flow nasal cannula as a respiratory support strategy in adults Acute hypoxemic Post-operative Peri-intubation Post-extubation respiratory failure NHF is preferred to COT in high No recommendation is respiratory fai
Slide 29: Hospital Respiratory Support
Hospital Respiratory Support OUR PURPOSE Improving care & outcomes through inspired and world- leading healthcare solutions
Slide 30: Home Respiratory Support - myAirvo
Home Respiratory Support -myAirvo Dr Robert Kirton Marketing Manager
Slide 31: myAirvo
myAirvo • Better patient outcomes • Reduce chronic patients hospital • Major cost of care • Initial target COPD
Slide 32: myAirvo - Care Continuum
myAirvo - Care Continuum • Chronic patient has respiratory exacerbation Hospital • Treated with AIRVO/Optiflow in hospital • Discharged from Hospital • Prescribed myAirvo for home use
Slide 33: myAirvo - Nasal High Flow Therapy
myAirvo - Nasal High Flow Therapy • Humidified air for respiratory support − Body temperature and 100% Humidified • Essential for therapy tolerance • Essential for improving mucus clearance − 2 to 60 l/min of gas flow • Making breathing easier • Wash out CO2 • If oxygen required − Can be added into
Slide 34: myAirvo – Who uses it?
myAirvo – Who uses it? Anyone with a Chronic Respiratory Disease Other respiratory Initial focus is COPD conditions • 3rd leading chronic killer (WHO) • Bronchiectasis • Asthma • 6-8% of the population • Cystic Fibrosis • Estimates ~ 384 M people worldwide • ILD / IPF • Limited treatment options • C
Slide 35: COPD – Chronic Obstructive Pulmonary Disease
COPD – Chronic Obstructive Pulmonary Disease Debilitating and incurable Progressive disease Can slow progression and improve quality of life Reduce exacerbations and going to hospital “COPD is like ‘spending ten years drowning,’ to quote one of my patients’ progressive dyspnea gradually erodes the p
Slide 36: GOLD characterisation of COPD
GOLD characterisation of COPD • Global Strategy for the Diagnosis, FEV1 Management, and Prevention of % predicted COPD Gold 1 ≥80 • Degree of COPD is characterized by the airflow limitation Gold 2 50-79 (obstructive) − “How hard to breath in and out” − As disease progresses, get harder Gold 3 30-49
Slide 37: GOLD characterisation of COPD
GOLD characterisation of COPD • Global Strategy for the Diagnosis, Management, and Prevention of COPD C D Increasing exacerbations • Degree of COPD is characterized by the airflow limitation (obstructive) − “How hard to breath in and out” − As disease progresses, get harder A B • A combination of ex
Slide 38: COPD: Key Published Clinical Evidence
COPD: Key Published Clinical Evidence
Slide 39: Quality of Clinical Evidence
Quality of Clinical Evidence Establish causality bias GUIDELINES: Clinical practice guideline, review of systematic reviews with recommendations. Guidelines Systematic review with meta-analysis SYSTEMATIC REVIEWS: e.g. Cochrane Collaboration Review Synthesizes and critically analyses data from RCTs.
Slide 40: Quality of Clinical Evidence
Quality of Clinical Evidence Establish causality bias GUIDELINES: Clinical practice guideline, review of systematic reviews with recommendations. Guidelines Systematic review with meta-analysis Optiflow systems including Airvo SYSTEMATIC REVIEWS: e.g. Cochrane Collaboration Review Synthesizes and cr
Slide 41: Quality of Clinical Evidence
Quality of Clinical Evidence Unstable Higher Acuity Publications featuring NHF for respiratory support in adults Guideline Guidelines Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observati
Slide 42: Quality of Clinical Evidence
Quality of Clinical Evidence Unstable Higher Acuity Publications featuring NHF for respiratory support in adults Guideline Guidelines Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observati
Slide 43: Quality of Clinical Evidence
Quality of Clinical Evidence Stable Low Acuity Publications featuring NHF for respiratory support in stable adults Guideline Guidelines Systematic review Critical review with meta-analysis Systematic review Interventional Clinical outcome controlled trial Physiological/Pilot controlled trial Observa
Slide 44: myAirvo – Growing Clinical evidence
myAirvo – Growing Clinical evidence Many studies underway to Early evidence strengthen clinical very promising evidence COPD studies = 13 Pulmonary rehab studies = 5 (COPD) = 5 (other diseases) Needs to change Other disease studies = 5 clinical practice
Slide 45: Summary
Summary • Many potential patients for myAirvo in the home • COPD a major market opportunity with largely unmet need • Growing clinical evidence • Changing clinical practice
Slide 46: Surgical Humidification
Surgical Humidification Winston Fong VP Surgical Technologies
Slide 47: Intro – Laparoscopy and laparotomy
Intro – Laparoscopy and laparotomy 14M 6M Laparoscopy Laparotomy procedures procedures 1 2 1. https://www.thestar.com.my/lifestyle/health/2017/05/07/a-keyhole-to-health; 2. Sugarbaker PH. Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy. Translation
Slide 48: Cold dry exposure to the patient
Cold dry exposure to the patient • Patient is exposed to cold and dry CO2 (laparoscopy) or ambient air (laparotomy) during surgery • Very different to natural physiological state (warm and wet) • Cold and dry CO2 causes evaporation which results in loss of heat and moisture from patient
Slide 49: What's the impact from cold dry exposure?
What’s the impact from cold dry exposure? CONTROL COLD, DRY Hypothermia Evaporative heat loss due to exposure to cold, dry CO2 and/or cold, dry operating room environment AT THE START OF INSUFFLATION AFTER 2 HOURS OF INSUFFLATION Tissue/Cell damage Effect of cold, dry CO2 and/or cold, dry operating
Slide 50: Implications of Hypothermia and Tissue/Cell damage
Implications of Hypothermia and Tissue/Cell damage Intraoperative Postoperative Hypothermia Surgical site infection Adhesions Peritoneal Tumor Metastasis Tissue / Cell damage
Slide 51: Surgical Humidification with HumiGard
Surgical Humidification with HumiGard • Surgical Humidification Platform − Tuned to deliver warm humidified CO2 • Humidified Consumables Kit − Thermally insulated tube – prevents the loss of heat and humidity to the theatre environment − Optimised for Operating Room environments
Slide 52: Growing the clinical evidence
Growing the clinical evidence Surgical Humidification research publications per annum 14 12 10 8 6 4 2 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Underway
Slide 53: Benefit of improved patient outcomes
Benefit of improved patient outcomes Costs of Care in the Operating Room • 30% of hospital admissions are 38% through the Operating theatres. These admissions represent 50% 7% Medical Supplies of hospital costs Other direct • Cost of a hospital stay after a 9% Indirect (i.e. hospital surgical proced
Slide 54: Summary
Summary • Surgical humidification plays a key part in establishing a third market within the hospital. • Right for the patient, good for the caregivers and hospital systems • ~20M patients (14M Lap, 6M Open) globally
Slide 55: Global Reach Sales & Marketing
Global Reach Sales & Marketing Justin Callahan - President North American Operations
Slide 56: Positioning
Positioning Value vs Cost $8000 $7000 ~$8000 Value $6000 ~$6000 Cost benefit COPD average $5000 from reimbursement COPD average reduced $4000 Cost of stay cost of stay escalation $3000 $2000 $1000 F&P Optiflow Conventional Higher cost oxygen therapy therapy consumables
Slide 57: Changing Clinical Practice
Changing Clinical Practice Using clinical evidence to drive change Multi layered with multiple stakeholders Insert image of products in action and Building confidence with usage inline or Sales talking with with the evidence, demonstrating clinician value Products in each care area builds familiarit
Slide 58: Opportunity across the Care Continuum
Opportunity across the Care Continuum ICU ED WARD HOME Invasive Ventilation Noninvasive OSA Ventilation Optiflow Nasal High Flow
Slide 59: Reach & Expertise
Reach & Expertise Acute Care Homecare Focused Sales Team Focused Sales Team • Sales teams need to be experts in the • Developing strong collaborative clinical application across the care relationships with Key Opinion Leaders continuum • Manage complex supply chain • Utilize multiple platforms to ac
Slide 60: Global reach in Developing Markets
Global reach in Developing Markets Bryan Peterson - General Manager International Sales - ROW
Slide 61: Changing Clinical Practice
Changing Clinical Practice Evolution of a therapy to change clinical practice − Therapy/Product Development • Ideas / observations • Improvements to therapy with existing technology • Refinement of ideas / development of prototypes, constant improvement • Clinical evaluation − Clinical Development •
Slide 62: Our Global Coverage
Our Global Coverage Our people are located in 45 countries Sell into more than 120+ countries With more than 180+ Distributors
Slide 63: The Market Development Curve
The Market Development Curve
Slide 64: The Market Development Curve
The Market Development Curve Developed Markets Developing Markets
Slide 65: Enhancing Distribution Partners
Enhancing Distribution Partners Distribution Partners • Independent local company • Sales/Marketing team • Finance/Operations team • May distribute few or many products • Typically 10-100 people Multi-channel distribution • Focus • Training & support • Strategic alignment
Slide 66: Story remains the same
Story remains the same • Changing Clinical Practice • Reducing escalation of care • Enhancing the de-escalation of care and avoidance of rebound • Sustainable sales
Slide 67: Lessons learned accelerates growth
Lessons learned accelerates growth • Knowledge and learnings from the Developed markets drives growth in Developing markets Developed − Same patients Market − Same environment, − Potentially different resources available • Working with KOL’s, educating clinicians on therapy, supporting broad utilisa
Slide 68: Improving care and outcomes
Improving care and outcomes People Helping People